UPDATE: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals to Hold, Lowers PT

In a report published Friday, Cantor Fitzgerald downgraded its rating on Ligand Pharmaceuticals LGND from Buy to Hold, and lowered its price target from $28.00 to $23.00. Cantor Fitzgerald noted, “After attending a Hepatitis C lecture and speaking with physicians at the New York Society for Gastrointestinal Endoscopy on December 19 we are lowering our estimates on Promacta in the Hepatitis C (HCV) indication from $337M to $67.5M in 2017. Our reasons are as follows: (1) Physician awareness of Promacta in HCV is minimal a month after its approval and reimbursement is believed to be non-existent; (2) doctors indicated that low platelet levels are not a key reason for keeping very sick HCV patients off interferon treatments; (3) presenters indicated that effective non-interferon treatments are expected to be introduced in the next 2-3 years (which does not allow time for significant Promacta ramp, in our view); and (4) weekly prescription trends are not showing any significant pick-up since approval. We realize it is still quite early in the HCV launch, but initial signals thus far are not encouraging, so we are moving to the sidelines and introducing a HOLD rating.” Ligand Pharmaceuticals closed on Thursday at $20.42.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsBiotechnologyCantor FitzgeraldHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!